A Phase II Clinical Trial of PRX-00023 Therapy in Localization-Related Epilepsy

Trial Profile

A Phase II Clinical Trial of PRX-00023 Therapy in Localization-Related Epilepsy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Naluzotan (Primary)
  • Indications Epilepsy
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Apr 2016 Planned End Date changed from 1 May 2018 to 1 Aug 2017 as reported by ClinicalTrials.gov record.
    • 11 Apr 2016 Planned primary completion date changed from 1 May 2018 to 1 Aug 2017 as reported by ClinicalTrials.gov record.
    • 12 May 2015 Planned End Date changed from 1 Aug 2015 to 1 May 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top